Phaseline

Companies › Haisco Pharmaceutical Group

Haisco Pharmaceutical Group: clinical trials, targets and expected readouts

18 active drug programs in 33 registered trials: 17 Phase 1, 9 Phase 2, 5 Phase 3, 2 Phase 4; Oncology, Other, Immunology, Respiratory; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cipepofol (HSK3486)
GABA-A receptor; anion channel agonist
GABRA1, GABRB2, GABRG2, GABRB3, GABRA4Phase 4Anesthesia; Myocardial Injury–
HSK31858–Phase 3Non-cystic Fibrosis Bronchiectasis; Healthy Subjects; Non-cystic Fibrosis Bronchiectasis (NCFBE)Nov 2026
HSK39297
complement C5 inhibitor
–Phase 3IgA Nephropathy (IgAN); Paroxysmal Nocturnal Hemoglobinuria; Lupus Nephritis (LN); Paroxysmal Nocturnal Hemoglobinuria (PNH)Dec 2026
HSK39004 inhalation suspension–Phase 3COPD (Chronic Obstructive Pulmonary Disease); COPD PatientsSep 2027
HSK31679–Phase 3MASH - Metabolic Dysfunction-Associated SteatohepatitisJun 2029
HSK55718–Phase 2Pain After SurgeryNov 2026
HSK47388–Phase 2Ulcerative Colitis (UC)Oct 2027
HSK39004 Dry Powder Inhaler–Phase 2Chronic Obstructive Lung Disease (COLD); Chronic Obstructive Pulmonary Disease (COPD)–
HSK46575–Phase 1m CRPCDec 2026
HSK56630–Phase 1Healthy VolunteerDec 2026
HSK44459 Cream–Phase 1PsoriasisMar 2027
HSK40118
EGFR inhibitor
EGFRPhase 1NSCLCJun 2027
HSK42360
BRAF V600 inhibitor
BRAFPhase 1Solid Tumors; Malignant Brain TumorsJul 2027
HSK47977
BTK inhibitor
–Phase 1NHLDec 2027
HSK41959
MTAP inhibitor
MTAPPhase 1Advanced Solid TumorsMay 2028
HSK42360-Na
BRAF V600 inhibitor
BRAFPhase 1Solid Tumors (Phase 1); Metastatic Colorectal Cancer (CRC)Dec 2028
HSK46256
PARP1 inhibitor
PARP1Phase 1Advanced Solid Tumor (Phase 1)Dec 2028
HSK55879–Phase 1Healhty–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07134478HSK31858Phase 1Healthy SubjectsOtherDec 2024
NCT06740201Cipepofol (HSK3486)Phase 4AnesthesiaOtherMar 2025
NCT07140328HSK39004 Dry Powder InhalerPhase 2Chronic Obstructive Lung Disease (COLD)RespiratoryJul 2025
NCT07140328HSK39004 Dry Powder InhalerPhase 2Chronic Obstructive Lung Disease (COLD)RespiratoryJul 2025
NCT07152288HSK39297Phase 1Paroxysmal Nocturnal Hemoglobinuria (PNH)HematologySep 2025
NCT07331402HSK39004 inhalation suspensionPhase 2COPD PatientsRespiratoryDec 2025
NCT07521345HSK55879Phase 1HealhtyOtherJun 2026
NCT07108699HSK39004 Dry Powder InhalerPhase 2Chronic Obstructive Pulmonary Disease (COPD)RespiratoryAug 2026
NCT07915011HSK31858Phase 1Non-cystic Fibrosis Bronchiectasis (NCFBE)RespiratoryNov 2026
NCT07915024HSK31858Phase 1Non-cystic Fibrosis Bronchiectasis (NCFBE)RespiratoryNov 2026
NCT07533786HSK55718Phase 2Pain After SurgeryOtherNov 2026
NCT06660992HSK31858Phase 3Non-cystic Fibrosis BronchiectasisRespiratoryNov 2026
NCT07616700HSK39297Phase 2IgA Nephropathy (IgAN)GenitourinaryDec 2026
NCT07913009HSK31858Phase 1Non-cystic Fibrosis Bronchiectasis (NCFBE)RespiratoryDec 2026
NCT07007910HSK46575Phase 1m CRPCOncologyDec 2026
NCT07580794HSK56630Phase 1Healthy VolunteerOtherDec 2026
NCT07623486HSK44459 CreamPhase 1PsoriasisImmunologyMar 2027
NCT06050980HSK40118Phase 1NSCLCOncologyJun 2027
NCT06745622HSK39297Phase 2Paroxysmal Nocturnal HemoglobinuriaHematologyJun 2027
NCT06536400HSK42360Phase 1Solid TumorsOncologyJul 2027
NCT07583849HSK39004 inhalation suspensionPhase 3COPD (Chronic Obstructive Pulmonary Disease)RespiratorySep 2027
NCT07028593Cipepofol (HSK3486)Phase 4Myocardial InjuryOncologyOct 2027
NCT07335055HSK47388Phase 2Ulcerative Colitis (UC)ImmunologyOct 2027
NCT07363460HSK39297Phase 2Lupus Nephritis (LN)ImmunologyNov 2027
NCT07390123HSK39297Phase 3IgA Nephropathy (IgAN)GenitourinaryDec 2027
NCT07283796HSK47977Phase 1NHLOncologyDec 2027
NCT06968572HSK41959Phase 1Advanced Solid TumorsOncologyMay 2028
NCT07561554HSK42360-NaPhase 1Solid Tumors (Phase 1)OncologyDec 2028
NCT07695142HSK46256Phase 1Advanced Solid Tumor (Phase 1)OncologyDec 2028
NCT07616375HSK31858Phase 3Non-cystic Fibrosis BronchiectasisRespiratoryJan 2029
NCT07158710HSK42360Phase 1Malignant Brain TumorsOncologyMay 2029
NCT07581951HSK31679Phase 3MASH - Metabolic Dysfunction-Associated SteatohepatitisGastroenterologyJun 2029
NCT07790510HSK42360-NaPhase 1Metastatic Colorectal Cancer (CRC)OncologySep 2029

Targets

BRAF (2) PARP1 (1) EGFR (1) GABRA1 (1) GABRB2 (1) GABRG2 (1) GABRB3 (1) GABRA4 (1) MTAP (1)

Companies with the same targets

AstraZeneca Pfizer Pierre Fabre Medicament Shanghai Henlius Biotech Ono Pharmaceutical Novartis Roche Johnson & Johnson (Janssen) Jiangsu Hansoh Pharmaceutical Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Jiangsu Hansoh Pharmaceutical Ono Pharmaceutical Sunshine Lake Pharma Beijing InnoCare Pharma Tech Abbisko Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.